News | Contrast Media | November 26, 2020

GE Healthcare Announces U.S. FDA approval of macrocyclic MRI Contrast Agent Clariscan in Pre-Filled Syringes

Clariscan in pre-filled syringes offers potential advantages for workflow safety and efficiency

GE Healthcare has received U.S. FDA approval of its macrocyclic gadolinium-based MRI contrast agent, Clariscan (gadoterate meglumine), in pre-filled syringes. #RSNA20

November 26, 2020 — GE Healthcare has received U.S. FDA approval of its macrocyclic gadolinium-based MRI contrast agent, Clariscan (gadoterate meglumine), in pre-filled syringes. Pre-filled with 10, 15 and 20mL of contrast agent, Clariscan’s ready-assembled, clear plastic syringes save time and reduce the risk of injury from broken glass, while the color-coded volume labels allow for easy identification of the required patient-specific volume. Its 2D data matrix contains scannable key information to be uploaded onto electronic medical systems, reducing the risk of manual data entry errors and helping to further increase workflow efficiency at medical centers.

Already available in glass vials and plastic polymer bottles, the approval of Clariscan in crystal clear polymer pre-filled syringes adds to the range of packaging solutions available to meet departmental needs and follows the recent FDA approval of Clariscan’s +PLUSPAK Pharmacy Bulk Package. This patented, pharmaceutical grade polypropylene bottle is the only FDA-approved polymer bottle for an MRI contrast agent.

With injuries from glass bottles making up an estimated 16 percent of sharps injuries in healthcare settings, Clariscan’s +PLUSPAK - and now plastic pre-filled syringes – both have the potential to improve workflow efficiencies while helping to reduce the associated risk of sharps injuries.  With the approach of the Radiological Society of North America (RSNA) 2020 Annual Meeting from November 29-December 5, GE Healthcare will focus on the theme of driving greater efficiency, an imperative to addressing the challenges of many health systems around the globe, especially in the context of the global COVID-19 pandemic.

Clariscan – now approved in over 70 countries globally – is indicated for intravenous use with magnetic resonance imaging (MRI) in brain (intracranial), spine and associated tissues in adult and pediatric patients (including term neonates) to detect and visualize areas with disruption of the blood brain barrier (BBB) and/or abnormal vascularity. 

“The addition of pre-filled syringes expands the Clariscan portfolio to address a wider range of departmental requirements” said Mark Hibberd, M.D., Chief Medical Officer for GE Healthcare’s Pharmaceutical Diagnostics unit. “The potential timesaving and efficiency advantages further enhance operational workflow improvements for radiology departments”.

GE Healthcare’s Pharmaceutical Diagnostics unit develops and supplies imaging agents used to support around 100 million procedures per year globally, equivalent to three patients every second. Clariscan, approved by U.S. FDA in November 2019, is the latest in a growing range of imaging agents available in the U.S. which are used across MRI, X-ray/CT and ultrasound to enhance the image and support diagnosis.

Clariscan is manufactured in Norway using a proprietary manufacturing process. As with all GE Healthcare contrast media products, all stages of manufacturing, from development of the active pharmaceutical ingredient (API) to finished product, are managed entirely by GE. Clariscan is available in single dose vials of 10, 15 and 20 mL; 100 mL Pharmacy Bulk Package in +PLUSPAK polymer bottles; and now 10, 15 and 20mL clear plastic pre-filled syringes.

For more information: www.gehealthcare.com

Related Content

New Module Creates a Warped MRI Scan that Matches Real-Time Ultrasound Results (Graphic: Business Wire)

New Module Creates a Warped MRI Scan that Matches Real-Time Ultrasound Results (Graphic: Business Wire)

News | Artificial Intelligence | May 07, 2021
3D aMRI not only provides a stunning look inside the "beating brain", but it can also measure this physiological motion in all directions. Here, the amplitude of brain motion is overlayed for each brain slice and orientation in 3D. Image credit: 3D aMRI method outlined in Abderezaei et al. Brain Multiphysics (2021); Terem et al. Magnetic Resonance in Medicine (2021).

3D aMRI not only provides a stunning look inside the "beating brain", but it can also measure this physiological motion in all directions. Here, the amplitude of brain motion is overlayed for each brain slice and orientation in 3D. Image credit: 3D aMRI method outlined in Abderezaei et al. Brain Multiphysics (2021); Terem et al. Magnetic Resonance in Medicine (2021).

News | Magnetic Resonance Imaging (MRI) | May 06, 2021
May 6, 2021 — Magnetic Resonance Imaging
Research finds that a commonly used risk-prediction model for lung cancer does not accurately identify high-risk Black patients who could benefit from early screening

Getty Images

News | Lung Imaging | May 05, 2021
May 5, 2021 — Lung cancer is the third most common cance
After radiosurgery concurrent with nivolumab in 59-year-old patient with melanoma BM (patient 1; Supplemental Tables 3 and 5), F-18 FET PET at follow-up 12 weeks after treatment initiation (bottom row) shows significant decrease of metabolic activity (TBRmean, ?28%) compared with baseline (top row), although MRI changes were consistent with progression according to iRANO criteria. Reduction of metabolic activity was associated with stable clinical course over 10 mo. CE = contrast-enhanced. Image created by

After radiosurgery concurrent with nivolumab in 59-year-old patient with melanoma BM (patient 1; Supplemental Tables 3 and 5), F-18 FET PET at follow-up 12 weeks after treatment initiation (bottom row) shows significant decrease of metabolic activity (TBRmean, ?28%) compared with baseline (top row), although MRI changes were consistent with progression according to iRANO criteria. Reduction of metabolic activity was associated with stable clinical course over 10 mo. CE = contrast-enhanced. Image created by N. Galldiks et al., Research Center Juelich, Juelich, Germany.

News | PET Imaging | May 05, 2021
May 5, 2021 — For patients with brain metastases, amino acid ...
When working with a vendor on project implementation, it is critical to focus on the actual execution of the implementation

Getty Images

Feature | Radiology Business | May 05, 2021 | By Jef Williams
You have selected a vendor. Congratulations.
Building the right infrastructure today will ensure the needed tools are there tomorrow, whatever the challenge may be

Getty Images

Feature | Radiology Business | May 05, 2021 | By Tom Cheesewrite in collaboration with Ludger Philippsen
The COVID-19 pandemic came as a shock, but not a